Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nuvaxovid + Efluelda
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Nuvaxovid + Efluelda is an investigational combination vaccine being developed by Sanofi in collaboration with Novavax to protect against seasonal influenza and COVID-19. The vaccine candidate pairs Sanofi's marketed high-dose trivalent inactivated split-virion influenza vaccine, Efluelda (marketed as Fluzone High-Dose in the US), with Novavax's protein-based adjuvanted COVID-19 vaccine, Nuvaxovid (NVX-CoV2705). Efluelda targets the hemagglutinin proteins of influenza virus strains, while Nuvaxovid targets the SARS-CoV-2 spike protein. Nuvaxovid utilizes recombinant nanoparticle technology and is formulated with Novavax's proprietary saponin-based Matrix-M adjuvant to enhance the immune response. The combination vaccine is currently in Phase 3 clinical development in Europe, evaluating its safety, tolerability, and immunogenicity in adults aged 60 and older.
- Other names
- Efluelda + NuvaxovidFluzone High-Dose + NuvaxovidIIV-HD + NVXC19IIV-HD + NVXC19 combinationNuvaxovid + Fluzone High-Dose
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SA-glycans (Host sialic acid-containing glycans)SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on Nuvaxovid + Efluelda.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuvaxovid + Efluelda.